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Introduction: Cord blood is utilized as a useful source of cells for hematopoietic stem cell transplantation,
but this can be problematic because there is a high rate of graft failure compared to when other graft
sources are used. A previous study successfully avoided graft failure by simultaneously grafting cord
blood and bone marrow mesenchymal stem cells (MSCs) that are considered to function in the he-
matopoietic stem cell niche of the bone marrow.
Organs of the fetal life support system such as the placenta and umbilical cord, which are discarded after
delivery, contain an abundance of MSCs as well as cells that function in the hematopoietic stem cell
niche. By identifying and collecting such cells and subsequently co-transplanting them with cord blood,
an improvement in graft survival can be anticipated.
Methods: Three types of stem cells, amnion epithelial stem cells (AM-Epi), amnion mesenchymal stem
cells (AM-Mes), and Wharton's jelly (WJ)-MSCs, all of which can be isolated and cultured from the
placenta amnion or umbilical cord WJ, were investigated for the expression of hematopoietic stem cell
niche markers and for their capabilities to maintain hematopoietic stem cells when co-cultured with
cord blood hematopoietic stem cells.
Results: All types of isolated cells showed proﬁles that met the MSC minimal criteria according to surface
marker analysis. In addition, all cell types expressed the hematopoietic stem cell niche marker stromal
cell-derived factor-1 (SDF-1) (in order: AM-Epi > WJ-MSCs [ AM-Mes), although the expression
declined with further passaging.
After 5 days of co-culturing with cord blood CD34þ cells, the percentages of CD34þ, CD45 cells were:
AM-Epi 37.8%, AM-Mes 38.8%, WJ-MSCs 27.3%, and ﬁbroblasts 27.4%; and the number of CFU-GM colonies
were: AM-Epi 255.5 ± 21.6, AM-Mes 246.3 ± 28.5, WJ-MSCs 118.3 ± 11.8, ﬁbroblasts 147.8 ± 19.0, and NC
121.3 ± 6.5. Statistical analyses demonstrated that AM-Epi and AM-Mes produced signiﬁcantly greater
numbers of CFU-GM compared to WJ-MSC, ﬁbroblasts, or NC (p < 0.05).
Conclusions: These ﬁndings indicated that cells derived from the fetal life support system such as AM-Epi
and AM-Mes can be anticipated as potential cell sources for clinical application in cell therapies for the
purpose of enhancing graft survival during hematopoietic stem cell transplantation.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).ishikawa).
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Cord blood transplantation involves very little risk to the donor,
and the process can be coordinated readily. Due to these advan-
tages, there has been a rapid increase in the number of such
transplantations performed in recent years. On the other hand,
there is a major issue with this particular transplantation in that
there is a high incidence of graft failure (10e20%) compared to
other graft sources [1]. Some of the causes of the high rate of graft
failure include fewer transplanted cells and the virtual absence of
stromal cells that possess the ability to support hematopoietic cells
compared to bone marrow transplantation. To prevent graft failure,
a previous study simultaneously transplanted cord blood and bone
marrow mesenchymal stem cells (MSCs) that support hematopoi-
etic stem cells in the bone marrow microenvironment, and
demonstrated that graft survival is improved using this co-
transplantation procedure [2]. However, because bone marrow
MSCs are normally difﬁcult to collect and prepare from the recip-
ient or from cord blood donors, transplantation is typically per-
formed today using grafts from HLA-mismatched related donors.
Moreover, a relatively invasive procedure is required to collect the
bone marrow from healthy donors.
It has been gradually discovered that multipotent stem cells
such as MSCs are present in the fetal life support system including
the placenta and umbilical cord, and there is a high probability that
these tissues contain cells that function as a part of the hemato-
poietic stem cell niche. Several different types of stem cells are
present in the placenta including those that can differentiate into
mesenchymal tissues such as bone, cartilage, and adipose tissue as
well as those that possess a high immune tolerance [3]. In partic-
ular, the placenta amnion is physically located closest to the fetus,
allowing for procedures such as tissue collection to be performed
readily. The amnion, together with the chorion and decidua, form
the fetal membrane and produce amniotic ﬂuid to encase the fetus.
The amnion is composed of two types of multipotent stem cells
e epithelial cells (amnion epithelial stem cells or “AM-epi”) and
mesenchymal cells (amnion mesenchymal stem cells, or “AM-
Mes”) e and both types of cells are known to differentiate into the
three germ layers, exhibit high immune tolerance, and show anti-
inﬂammatory effects [4e6]. Methods to isolate and culture these
cells via enzymatic treatment have been established previously [7],
and these cells are anticipated for their potential in future clinical
application [8]. It has also been demonstrated that the placenta that
is alongside the aorta-gonad-mesonephros region is an essential
site for hematopoiesis during embryonic and fetal stages [9e11].
Furthermore, it has been reported that the human full-term
placenta also contains hematopoietic stem cells, and that a full-
term placenta cell line exhibiting MSC morphology supports the
maintenance of hematopoietic stem cells [12]. The umbilical cord,
which is covered in a sheath composed of amnion, contains two
umbilical arteries and one umbilical vein, and its stroma is ﬁlled
with a matrix calledWharton's jelly (WJ) that is composed of white
mucopolysaccharides (Fig. 1). This WJ is rich in MSCs and is known
to demonstrate multipotency and differentiate into bone, cartilage,
adipose tissue, as well as the nerves [13]. Because it is possible to
easily isolate and grow these cells using procedures such as the
explant method or collagenase enzymatic treatment, they are
highly anticipated for their potential application in the clinical
setting [14].
These methods of cell collection from the fetal life support
system do not entail invasive procedures to the donors. Moreover,
because these tissues are typically discarded after delivery, few
ethical issues are related to the clinical usage of these cells. In
addition, it is possible to collect and prepare cells from the same
individual as the cord blood donor. Therefore, stem cells derivedfrom the fetal life support system can be anticipated as new sources
of cells for cell therapy for the purpose of preventing cord blood
graft failure. However, the location of cells that exhibit hemato-
poietic stem cell niche function and the capacity of such cells to
support hematopoiesis after they are isolated and cultured have yet
to be elucidated in detail in such tissues.
Therefore, in the present study, we focused on three different
types of stem cells that can be isolated and cultured from the
placenta amnion and umbilical cordWJ and assessed the changes in
the expression of hematopoietic stem cell niche markers such as
stromal cell-derived factor-1 (SDF-1) and nestin. Furthermore, I
examined the capacity of these cells to support hematopoietic stem
cells when they were co-cultured with cord blood hematopoietic
stem cells. Based on these results, we endeavored to identify
placenta- and umbilical cord-derived cells that maintain the he-
matopoietic stem cell niche.
2. Materials and methods
2.1. Human placenta and umbilical cord
Human placenta and umbilical cord were collected from preg-
nant women who underwent a planned C-section at 36e39 weeks
of gestation at Nihon University Itabashi Hospital. Collected tissues
were stored in phosphate-buffered saline (PBS) at room tempera-
ture and were used for experiments within 24 h of collection.
Informed consent was obtained from the pregnant women prior to
collecting a portion of the tissues that were planned to be discarded
after delivery. All experiments using human fetal life support sys-
tem (placenta and umbilical cord) were approved by the Clinical
Research Review Board at Nihon University Itabashi Hospital and
conducted in accordance with the principles of the Declaration of
Helsinki (Approval number RK-111209-6).
2.2. Cell culture and preparation
2.2.1. HESS-5 cells
The stromal cell line HESS-5 was established from the bone
marrow of irradiated C3H/HeN mice and was a generous gift from
Dr. Takashi Tsuji of the Department of Biological Science and
Technology at Tokyo University of Science [15]. Cells were cultured
in Minimum Essential Medium (MEM) Alpha (Invitrogen) con-
taining 10% horse serum (Lot 8092930, Invitrogen, Carlsbad, CA) in
5% CO2 at 37 C. Cells were split once a week at a ratio of 1:5.
2.2.2. Human ﬁbroblasts
Fibroblasts derived from human skin were purchased from
Lonza (Walkersville, MD) and were cultured in Dulbecco's modiﬁed
Eagle medium (DMEM, Life Technologies, Carlsbad, CA) containing
10% fetal bovine serum (FBS, SAFC Biosciences, St. Louis, MO) in 5%
CO2 at 37 C. Fibroblasts were split at a 1:5 ratio approximately
every 5 days, and ﬁfth generation (P5) cells were used.
2.2.3. CD34þ cells from human cord blood
Of the human cord blood specimens provided to the Cord Blood
Processing and Storage Facility at Nihon University Itabashi Hos-
pital, those that could not be prepared for further use or preserved
due to an insufﬁcient number of nucleated cells were used in the
experiments within 24 h of collection. Cord blood monocytes were
isolated using a gradient centrifugation method. For every 35 ml of
cord blood, approximately 15 ml of blood cell isolation solution
(Lymphoprep: density: 1.077 g/cm3, Axis-Shield Poc, Oslo, Norway)
was used. After placing the blood cell separation solution in a tube,
cord blood was slowly layered on top and centrifuged for 30 min at
350e400  g. Subsequently, the monocytes were fractionated by
Fig. 1. Umbilical cord and placenta.
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tion. CD34þ cells were isolated from the collected human cord
blood monocytes using magnetic beads. In the magnetic beads
method, CD34þ cells were isolated using the CD34 MicroBeads Kit
(Miltenyi Biotec, Bergisch Gladbach, Germany) and separation
columns for positive selection (LS Columns, Miltenyi Biotec) ac-
cording to the manufacturer's protocol for each kit. To collect cell
fractions with greater purity, the above isolation protocol was
conducted twice. Isolated CD34þ cells were frozen in CELLBANKER
(Juji Field, Tokyo, Japan), stored in a liquid nitrogen tank, and
thawed immediately prior to use for experiments. Experiments
using human cord blood were approved by the Clinical Research
Review Board at Nihon University Itabashi Hospital and the Ethics
Committee at Tokyo Cord Blood Bank (Approval number 12-07-01).
2.2.4. Placenta amnion-derived stem cells
The placenta amnion was manually detached from the placenta
after delivery and processed using themethod previously described
by Barbati et al. [7]. The collected placenta amnion specimen wasFig. 2. Structure of thewashed with PBS. Because of the mesenchyme of amnion is spongy
layer, washing the amniotic membrane in PBS before separation
epithelial frommesenchyme, the mesenchyme layer is inﬂated and
increases thickness. In this way, epithelial layer and mesenchyme
layer can be easily separated (Fig. 2). AM-Epi and AM-Mes samples
were prepared as described below:
First, the amnion epithelial and mesenchymal tissues were cut
ﬁnely into 1-cm squares, submerged in DMEM containing 2.4 U/ml
Dispase (Roche Diagnostics, Mannheim, Germany), and incubated
with agitation for 20 min at 37 C. After each sample was centri-
fuged at 150  g for 15 min, the supernatant was discarded, 0.1%
Collagenase type II (SigmaeAldrich) was added, and the samples
were agitated for 60 min at 37 C. Subsequently, the samples were
strained with a 40-mm ﬁlter into a centrifuge tube and centrifuged
at 150  g for 15 min. These obtained samples were used in the
experiments as either AM-Epi or AM-Mes according to the origi-
nating tissue. Cells were cultured in MEM Alpha (Life Technologies)
containing 10% FBS in 5% CO2 at 37 C. Once the cells reached
80e90% conﬂuence, they were collected with 0.05% Trypsin-EDTAplacenta amnion.
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split at a 1:5 ratio approximately every 5 days. Cells cultured up to
P3 were used in the experiments.
2.2.5. Umbilical cord WJ-derived MSCs
Umbilical cord WJ-derived MSCs (WJ-MSCs) were prepared
using the explant method previously described byMcElreavey et al.
[16]. The umbilical cord samples were washed with PBS after
collection, and the umbilical cord artery and vein were mechani-
cally extracted and removed. WJ was ﬁnely minced using a scalpel
or ophthalmic scissors into ~5-mm diameter pieces that were
placed in a plastic dish and subsequently cultured in 10% FBS MEM
Alpha in 5% CO2 at 37 C. Once the adhered cells reached 80e90%
conﬂuence, they were collected with 0.05% Trypsin-EDTA and
subcultured into a plastic dish. Cells were subsequently split at a
1:5 ratio approximately every 5 days. Cells cultured up to P3 were
used in the experiments.
2.3. Immunohistochemistry
Frozen sections of human umbilical cord and placenta: Tissues
were washed with PBS after collection, ﬁnely minced to about 1 cm
in diameter, and ﬁxed in 4% paraformaldehyde (Muto Pure Chem-
icals, Tokyo, Japan) at 4 C for 24 h. Umbilical cord tissue was
dehydrated by submerging in saline containing sucrose, embedded
in O.C.T. compound (Sakura Finetechnical, Tokyo, Japan), and frozen
in liquid nitrogen. The placenta was embedded in O.C.T. compound
without the dehydration process after ﬁxing, and frozen in liquid
nitrogen. Tissue blocks were sectioned using a cryostat
(BRIGHT5040, Hacker Instruments & Industries, Winnsboro, SC) at
10-mm thickness and mounted on MAS-coated glass slides (Mat-
sunami Glass, Osaka, Japan).
Placenta amnion and umbilical cord samples for immunostain-
ing: First, tissues were minced ﬁnely and digested enzymatically.
Subsequently, cells (1 104/100 ml) were centrifugedwith CytoSpin
3 (Thermo Fisher Scientiﬁc, Waltham, MA) for 5 min at 600 rpm,
spread onto glass slides, and ﬁxed with 4% paraformaldehyde
(room temperature, 15 min).
Cultured cell sample preparation for immunostaining: Cells
were cultured for approximately 48 h in 24-well multiplates
(Becton Dickinson, Bedford, MA) containing a round cover glass
(Matsunami Glass) in each well. After the cells reached 80%
conﬂuence, they were ﬁxed in 4% paraformaldehyde (room tem-
perature, 15 min) and stained. Subsequently, the cover glasses were
removed and mounted on glass slides.
Immunoﬂuorescent staining of both tissue samples and cells
was performed in the following order: blocking, incubation with
primary antibody, incubation with secondary antibody, nuclear
staining, and application of mounting medium. For blocking, sam-
ples were incubated in Tris-buffered saline (TBS) containing 10%
goat serum (Vector Laboratories, Burlingame, CA) and 1% BSA
without agitation for 1 h at room temperature in a humid box. The
following primary antibodies were used: mouse anti-human
cytokeratin19 (CK19) antibody (Progen Biotechnik GmbH, Heidel-
berg, Germany) as an epithelial marker; rabbit anti-human SDF-1
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit
anti-human nestin antibody (SigmaeAldrich) as hematopoietic
stem cell niche markers; and rat anti-human stage-speciﬁc-antigen
3 (SSEA3) antibody (R&D Systems, Minneapolis, MN) and mouse
anti-human stage-speciﬁc-antigen 4 (SSEA4) antibody (R&D Sys-
tems) as embryonic stem cell markers. Samples were incubated
overnight with primary antibodies (diluted 1:100 to 1:500 with 1%
BSA-TBS) in a humid box at 4 C. On the following day, samples
were washed with PBS and incubated with ﬂuorescent-labeled
secondary antibodies (Alexa Fluor 594 goat anti-rabbit IgG, AlexaFluor 594 goat anti-rat IgM, Alexa Fluor 680 goat anti-rabbit, Invi-
trogen) diluted with 1% BSA-TBS at 1:500 for 1 h at room temper-
ature in a humid box. The samples were washed with PBS again,
stained with 5 mg/ml Hoechst 33342 (SigmaeAldrich) for nuclear
staining for 15 min at room temperature, and subsequently washed
with distilled water. FluoromountG (Southern Biotech, Birming-
ham, AL) was using as the mounting medium, and all samples were
visualized and imaged with a confocal laser scanning microscope
(FV10i-SW, Olympus, Tokyo, Japan).
2.4. Flow cytometry
AM-Epi, AM-Mes, and WJ-MSCs (P2) were suspended in PBS
with 0.2% BSA, and samples of 1  106 cells/100 ml/tube were
prepared. To block non-speciﬁc binding, 0.1 ml PBS containing 10 ml
normal rabbit serum (Funakoshi, Tokyo, Japan) was added to each
tube and incubated without agitation at room temperature for
10 min. After washing the cells with PBS (0.2% BSA), 5 ml phycoer-
ythrin (PE)-labeled anti-human CD90, CD73, CD11b, CD19, or HLA-
DR antibody (BD Biosciences) or allophycocyanin (APC)-labeled
anti-human CD105, CD34, or CD45 antibody (BD Biosciences) was
added to each cell suspension tube and incubated in the dark for
30 min at 4 C. For negative controls, PE- or APC-labeled mouse
IgG1 antibody (BD Biosciences) was used following the above
protocol. After cells were washed and suspended in 0.4 ml PBS
(0.2% BSA), they were strained with a mesh ﬁlter into 5-ml FACS
tubes (BD Falcon, Franklin Lakes, NJ). In each tube, 5 ml of 7-
aminoactinomycin D (7AAD, BD Biosciences) was added to detect
dead cells. Cell surface antigens were screened with a FACS Calibur
Flow Cytometer (Becton Dickinson), and the results were analyzed
with CellQuest software (Becton Dickinson).
2.5. Co-culture experiment of CD34þ cells from human cord blood
Cells derived from the placenta and umbilical cord and CD34þ
cells from human cord blood were co-cultured using a modiﬁed
protocol of a method described by Tsuji et al. [17,18]. Human ﬁ-
broblasts (Lonza) were used as negative control cells, and the
mouse stromal cell line HESS-5 was used as positive control cells.
AM-Epi, AM-Mes, WJ-MSCs (P3 for each cell type), HESS-5, or hu-
man ﬁbroblasts were seeded onto 6-well plates and cultured until
reaching conﬂuence (1  105/well). Subsequently, these cultured
cells were used as feeder cells and cultured together with CD34þ
cells from human cord blood (1  105 cells/well). For the growth
and maintenance of hematopoietic stem cells, Myelocult H5100
medium (MEM containing 12.5% horse serum, 12.5% FBS, 104 M 2-
mercaptoethanol; Stem Cell Technologies, Vancouver, Canada) with
50 ng/ml Stem Cell Factor (Wako) was used. After 5 days of co-
culture, non-adherent human cord blood cells were collected. Af-
ter the cells were washed with MEM Alpha and enumerated with a
hemocytometer, the growth rates of cells in reference to the pre-co-
culture cell count were determined. Furthermore, cell surface
markers on human cord blood cells after co-culture were analyzed
using ﬂow cytometry. Speciﬁcally, this ﬂow cytometry analysis was
conducted using the aforementioned method with double staining
with ﬂuorescein isothiocyanate (FITC)-labeled anti-human CD45
antibody (BD Biosciences) and APC-labeled anti-human CD34
antibody (BD Biosciences).
Negative controls were prepared for each sample, and quadrant
areas were determined.
2.6. Colony forming unit-granulocyte/macrophage (CFU-GM) assay
CFU-GM assay was conducted to assess the hematopoietic ac-
tivity of cord blood CD34þ cells after co-culturing with the three
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After AM-Epi, AM-Mes, WJ-MSCs, HESS-5, or human ﬁbroblasts
were co-cultured for 5 days with cord blood CD34þ cells, non-
adherent human cord blood cells were collected, seeded on a 35-
mm dish at 2  104 cells/ml in the methylcellulose-based me-
dium MethoCult H4034 Optimum (Stem Cell Technologies), and
cultured in 5% CO2 at 37 C. Colonies that formed after 14 days of
culture were enumerated (CFU-GM). Samples were compared in
triplicate, and statistical signiﬁcance was assessed.
2.7. Statistical analysis
Comparisons of quantitative data with the CFU-GM assay were
conducted using one-way analysis of variance (ANOVA) and a post-
hoc test (Tukey method), and p < 0.05 was considered statistically
signiﬁcant. GraphPad Prism software (Ver5.0a) was used for
analysis.
3. Results
3.1. Immunohistochemical study of the umbilical cord and placenta
tissues
To identify the location of cells that possess hematopoietic niche
function in the human umbilical cord and placenta tissues, frozen
sections of each tissue were created and immunostained with the
hematopoietic stem cell niche marker SDF-1. Representative
immunostained images of the umbilical cord tissue are shown in
Fig. 3. Cells that compose WJ in the umbilical cord tissue were
weakly positive for SDF-1 (Fig. 3A). SDF-1 was expressed at high
levels in amnion epithelial cells that were positive for CK19, an
epithelial marker (Fig. 3B). In contrast, endothelial cells and smooth
muscle cells that compose the umbilical arteries and veinwere both
SFD-1 negative.
A representative immunostaining image of the placenta tissue is
shown in Fig. 4. In the placenta amnion, which makes up the outer-
most layer of the placenta, CK19þ amnion epithelial cells and
CK19 amnion mesenchymal cells directly underneath the
epithelial cells were identiﬁed (Fig. 4A). SDF-1 expression was highFig. 3. Immunostaining of human umbilical cord tissue. Frozen sections of human umbilical
or with anti-SDF-1 antibody. Nuclei were stained with Hoechst 33342 (Hoechst). Figure sho
umbilical artery and umbilical vein. Scale bars: 50 mm.in the CK19þ amnion epithelial cells and extremely low in amnion
mesenchymal cells (Fig. 4A). Trophoblasts that compose the
placenta villi were also positively stained for SDF-1 (Fig. 4B). In
contrast, vascular cells and mesenchymal cells that are present in
the villi were SDF-1 negative.
These results demonstrated that SDF-1 is expressed in a differ-
ential manner depending on the site within the umbilical cord and
placenta tissues and is expressed at high levels especially in the
amnion epithelium that is present at the outer-most layer of the
umbilical cord and placenta.
3.2. Immunocytological analysis of cells derived from the fetal life
support system
Because stem cells that are present in the fetal life support
system exhibit high proliferative activities, they can be cultured and
grown after they have been isolated from the tissues with colla-
genase enzymatic treatment or the explant method. In the present
study, with consideration for the ease of isolating and culturing
cells from tissues and for the expression of SDF-1, we isolated cells
from the placenta amnion epithelium, placenta amnion mesen-
chyme, and umbilical cord WJ. The three different types of stem
cells (AM-Epi, AM-Mes, and WJ-MSCs) obtained after the isolation
procedures were cultured and morphologically compared by con-
ducting immunocytochemical analyses using hematopoietic stem
cell nichemarkers as well as embryonic stem cell markers. From 1 g
of placenta amnion epithelium or mesenchyme, approximately
3 105 stem cells were isolated through enzymatic digestion. From
1 g of umbilical cord, approximately 3  105 stem cells were iso-
lated using the explant method.
The immunostaining images of AM-Epi derived from placenta
amnion epithelium are shown in Fig. 5. In cytospin samples of cells
isolated from the amnion epitheliumwith enzymatic digestion, the
majority of the cells expressed CK19 (Fig. 5, Cytospin, CK19), veri-
fying that these cells are indeed derived from the amnion epithe-
lium. CK19þ cells had high levels of SDF-1 expression (Fig. 5,
Cytospin, SDF-1). The hematopoietic stem cell niche marker nestin
and the human embryonic stem cell marker SSEA4 were also
expressed in many cells (Fig. 5, Cytospin, nestin, SSEA4). Stainingcord tissue were prepared and immunostained with anti-cytokeratin19 (CK19) antibody
ws the Wharton's jelly (A) and the umbilical cord amnion (B). The arrows indicate the
Fig. 4. Immunostaining of human placenta tissue. Frozen sections of human placenta tissue were prepared and immunostained with anti-CK19 antibody or with anti-SDF-1
antibody. Nuclei were stained with Hoechst 33342 (Hoechst). Figure shows the placenta amnion (A) and placenta villi (B). Scale bars: 50 mm.
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(Fig. 5, Cytospin, SSEA3). Splitting the isolated cells resulted in
satisfactory cell growth from P0 through P3. With passaging, the
cytoplasm expanded and hypertrophied, and the nuclei tended to
enlarge gradually. CK19 expression was evident up to P1 but
decreased from P2 and was virtually undetectable at P3 (Fig. 5,
P0eP3, CK19). SDF-1 and nestin expression also showed a tendency
to diminish after culturing, and although expression of both was
detectable up to P1, they markedly declined from P2 (Fig. 5, P0e3,
SDF-1, and nestin). Similarly, SSEA4 expression tended to decrease
after culturing; however, continual positive expressionwas evident
up to P3 in some cells (Fig. 5, P0e3, SSEA4). Virtually no SSEA3-
positive cells were detected after culturing (Fig. 5, P0e3, SSEA3).
Immunostaining of placenta amnion stroma-derived AM-Mes is
shown in Fig. 6. Most cells in the cytospin samples were CK19
(Fig. 6, Cytospin, CK19), verifying that these cells are derived from
the amnion mesenchyme. SDF-1 expression in AM-Mes was
markedly lower compared to that in AM-Epi (Fig. 6, Cytospin, SDF-
1). Nestin and SSEA4 were expressed in many cells, similar to AM-
Epi (Fig. 6, Cytospin, nestin, and SSEA4). Similar to AM-Epi, SSEA3
was negative in the majority of AM-Mes (Fig. 6, Cytospin, SSEA3).
Splitting the isolated cells resulted in satisfactory growth from P0 to
P3, and both the cytoplasm and nuclei tended to become larger
with passaging. SDF-1 was virtually undetectable from P1 with
subculturing (Fig. 6, P0eP3, SDF-1). Nestin and SSEA4 expression
also tended to diminish after culturing, and expression of both
markedly declined and could not be detected from P1 (Fig. 6, P0e3,
nestin, and SSEA4). Virtually no cells positive for SSEA3 were pre-
sent after culturing (Fig. 6, P0e3, SSEA3).
Immunostaining of WJ-MSCs derived from umbilical cord WJ is
shown in Fig. 7.
Because WJ-MSCs were collected using the explant method,
immunocytochemical analysis was conducted with P1 cells. Almost
all cells were CK19, conﬁrming that samples were not contami-
nated with epithelial cells (Fig. 7, P1, CK19). The cellular prolifera-
tive capacity was satisfactory up to P3, and similar to AM-Epi and
AM-Mes, the cytoplasm and nucleus of WJ-MSCs tended to
become enlarged with passaging (Fig. 7, P1e3, CK19). AlthoughSDF-1 was evident at P1, albeit at a low level, its expression
markedly declined with passaging, similar to AM-Epi and AM-Mes
(Fig. 7, P1e3, SDF-1). Nestin showed a relatively greater expression
at P1 compared to that of AM-Epi or AM-Mes. However, its
expression decreased from P2 and became virtually undetectable
(Fig. 7, P1e3, nestin). SSEA4 was also expressed in most P1 cells;
however, its expression showed a tendency to decrease with
passaging (Fig. 7, P1e3, SSEA4). SSEA3 expression was negative,
similar to AM-Epi and AM-Mes (Fig. 7, P1e3, SSEA3).
These results showed that in these stem cells derived from the
fetal life support system, expression of SDF-1, nestin, and SSEA4
was observed immediately after isolation, verifying the differences
in cell origins. However, cells that were grown through subcultur-
ing demonstrated a decline in the expression of these markers and
resulted in smaller morphological differences among the cell types.
3.3. Cell surface marker proﬁle of stem cells derived from the fetal
life support system
In cell surface marker analysis with ﬂow cytometry, all cell
types, AM-Epi, AM-Mes, and WJ-MSCs (P2), were positive for the
MSC markers CD73, CD90, and CD105 but were negative for the
blood cell markers CD34, CD45, CD19, CD11b, and HLA-DR (Fig. 8).
This particular proﬁle met the minimal criteria for MSCs [19]. In
addition, there were no obvious differences among these three
types of isolated stem cells in the percentages of CD73, CD90, or
CD105 þ cells. These results indicated that all three cell types, AM-
Epi, AM-Mes, and WJ-MSCs, exhibit MSC-like morphology at P2.
3.4. Co-culture experiment with cord blood CD34þ cells
To assess the abilities of the three types of stem cells derived
from the fetal life support system to maintain hematopoietic stem
cells, P3 cells were used as feeder cells and co-cultured with human
cord blood CD34þ cells, and the extent of cord blood cell prolifer-
ation and maintenance capacity of hematopoietic stem cells was
analyzed. CD34þ cells isolated from cord blood monocytes using
magnetic beads were analyzed with ﬂow cytometry to conﬁrm that
Fig. 5. Immunostaining of placenta amnion epithelial stem cells. After manually detaching the human placenta amnion epithelium, cells were isolated from the tissue via enzymatic
treatment and were analyzed using immunocytochemistry. Immunostaining with cytokeratin19 (CK19), SDF-1, nestin, SSEA4, and SSEA3 are shown in order from the top to bottom.
Passage 0 (P0), passage 1 (P1), passage 2 (P2), and passage 3 (P3) cells immediately after cytospin isolation are shown from left to right. Nuclei were stained with Hoechst 33342
(Hoechst). Scale bars: 50 mm.
E. Nishikawa et al. / Regenerative Therapy 4 (2016) 48e6154the purity was 90%. After 5 days of co-culture, cord blood cells
were collected and quantiﬁed. The cell count increased 5.8-fold in
AM-Epi, 7.6-fold in AM-Mes, and 6.5-fold in WJ-MSCs. A 4.6-fold
increase in the cell count of the positive control HESS-5 was
observed. In contrast, cell proliferationwas unstable when negative
control ﬁbroblasts were used as feeder cells; in some experiments,
the cell count increased, and in other experiments, no changes
were observed compared to the number of seeded cells. Moreover,
when cord blood CD34þ cells were cultured alone without feeder
cells, very little cell proliferationwas evident. The same experiment
was conducted three times using stem cells derived from the fetal
life support system from the same donor, and similar trends of
increased cord blood cells with co-culturewere demonstrated in all
three experiments (Fig. 9).
After co-culturing the cells, the percentages of the CD34þ
CD45 cell fraction, which is a marker for hematopoietic pro-
genitor cells, were analyzed with ﬂow cytometry. The resultsdemonstrated that this fraction accounted for 37.8% in AM-Epi,
38.8% in AM-Mes, 27.3% in WJ-MSCs, 60.0% in HESS-5, and 27.4%
in ﬁbroblasts. Both AM-Epi and AM-Mes, albeit not to the level of
positive control HESS-5, had signiﬁcantly greater percentages
than negative control ﬁbroblasts (Fig. 10). The same experiment
was conducted an additional two times using stem cells derived
from the fetal life support system from the same donor, and
similar results were obtained. These results indicated that AM-
Epi, AM-Mes, and WJ-MSCs support the proliferative and main-
tenance capacities of CD34 þ cells from human cord blood.
3.5. Hematopoietic activity of cord blood CD34þ cells after co-
culture
To determine the differentiation potential of cord blood CD34þ
cells into blood cells that were co-cultured with three different
types of stem cells derived from the fetal life support system, cord
Fig. 6. Immunostaining of placenta amnion mesenchymal stem cells. After manually detaching the human placenta amnion mesenchyme, cells were isolated and cultured after
enzymatic digestion, and subsequently analyzed by immunocytochemistry. Immunostaining with cytokeratin19 (CK19), SDF-1, nestin, SSEA4, and SSEA3 are shown in order from
top to bottom. Passage 0 (P0), passage 1 (P1), passage 2 (P2), and passage 3 (P3) cells immediately after cytospin isolation are shown from left to right. Nuclei were stained with
Hoechst 33342 (Hoechst). Scale bars: 50 mm.
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examined with the CFU-GM assay to compare the number of col-
onies formed among the different cell types (Fig. 11). CFU-GM
colonies for each cell type were (mean ± SD): 255.5 ± 21.6 for
AM-Epi, 246.3 ± 28.5 for AM-Mes, 118.3 ± 11.8 for WJ-MSCs,
271.3 ± 39.2 for HESS-5, 147.8 ± 19.0 for ﬁbroblasts, and
121.3 ± 6.5 for negative control (NC) without feeder cells. The CFU-
GM assay with cord blood CD34þ cells before co-culture resulted in
a colony population of 345.0 ± 33.9, demonstrating that the colony
formation capacity tended to be high even before the co-culture
experiments, although there were some variations among indi-
vidual samples. Statistical analysis showed that both AM-Epi and
AM-Mes had signiﬁcantly greater CFU-GM colonies compared to
WJ-MSCs, NC, or ﬁbroblasts (p < 0.05). These results indicated that
AM-Epi and AM-Mes exhibit high capacities to maintain hemato-
poietic stem cells and that the capacity levels were greater than
that of ﬁbroblasts or WJ-MSCs.4. Discussion
4.1. Immunohistochemical analysis of cells derived from the fetal
life support system
Immunohistochemical analysis of the human umbilical cord
and placenta showed that cells positive for the hematopoietic
stem cell niche marker SDF-1 were detected in the umbilical cord
amnion, umbilical cord WJ, placenta amnion, and placenta villi. In
the placenta tissue, SDF-1 was expressed at high levels especially
in the CK19þ amnion epithelium, but virtually no expression was
observed in the CK19 amnion mesenchyme. Amnion epithelial
cells are derived from embryonic ectoderm, and amnion mesen-
chymal cells arise from embryonic mesoderm. Due to such dif-
ferences in origins, these cells may inherently have differential
expression of SDF-1. On the other hand, the in vivo hematopoietic
stem cell niche marker nestin and the embryonic stem cell marker
Fig. 7. Immunostaining of WJ-derived mesenchymal stem cells. Cells were isolated and cultured from the human umbilical cord WJ by the explant method and analyzed with
immunocytochemistry. Immunostaining with cytokeratin19 (CK19), SDF-1, nestin, SSEA4, and SSEA3 are shown in order from top to bottom. Passage 1 (P1), passage 2 (P2), and
passage 3 (P3) cells are shown from left to right. Nuclei were stained with Hoechst 33342 (Hoechst). Scale bars: 50 mm.
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Fig. 8. Surface marker proﬁle of stem cells derived from the fetal life support system. Surface markers of AM-Epi, AM-Mes, and WJ-MSCs isolated from the fetal life support system
were analyzed using ﬂow cytometry. The red line indicates the isotype control.
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from the placenta amnion as well as in cells isolated from the
umbilical cord WJ. These ﬁndings are consistent with previous
reports that demonstrated expression of various stem cell markers
in the amnion epithelium, amnion mesenchyme, and WJ-derived
cells [4,5,20,21]. These ﬁndings suggested that these cells may
contain stem cell components that display hematopoietic niche
functions. Robin et al. found that a cell line generated from human
full-term placenta that possess the ability to maintain hemato-
poietic stem cells expresses MSC markers as well as several peri-
cyte markers, and postulated that these cells may originate from
pericytes that are present in the villous capillary [12]. In the
present study, we observed SDF-1 expression in the villous
trophoblast cells but not in the capillary endothelium or in its
vicinity in the placenta villi tissue. In terms of the isolation and
ex vivo proliferation of cells that exhibit hematopoietic niche
function, because the villous tissue is composed of numerous
different types of cells such as maternal cells (e.g., maternal blood)
and fetal cells, it would be extremely difﬁcult to isolate and grow
speciﬁc cells. For this reason, we excluded cells derived from
villous tissues for examination in the present study. The identiﬁ-
cation and analyses of hematopoietic niche cells located in this
region are future topics of investigation.In this study, I cultured cells from the epithelium and mesen-
chyme of the placenta amnion and from the umbilical cord WJ, and
conducted a morphological analysis by preparing three types of
stem cells (AM-Epi, AM-Mes, WJ-MSCs) using previously estab-
lished isolation and culture methods. Because there are no previous
studies that simultaneously compared cells derived from the same
donor, this study provides a novel perspective. Our results showed
that all three types of cells showed decreased expression of SDF-1,
nestin, and SSEA4 with further subculturing. Previous reports have
also demonstrated decreases in stem cell markers as well as
diminished multipotency with passaging [22,23]. These ﬁndings
suggested that culturing and repeatedly subculturing the cells may
reduce or eliminate the physiological functions of stem cells
derived from the fetal life support system. Based on these results,
we believe it is desirable to conduct further functional analysis
using cells that have gone through fewer passaging (P0 or P1) if
possible in all types of the stem cells derived from the fetal life
support system. SDF-1 is a chemokine whose expression is trig-
gered by hypoxic stimuli [24], and its expression may change
depending on the cell culture conditions. In the future, it may be
necessary to compare SDF-1 expression of these stem cells under
hypoxic stimuli conditions or to examine other markers of the
hematopoietic stem cell niche.
Fig. 9. Cord blood CD34þ cell counts after co-culture. Post-co-culture CD34þ cell counts normalized to pre-co-culture counts are shown. AM-Epi, AM-Mes, and WJ-MSCs all
showed a similar level of proliferation as the positive control HESS-5. The same experiment was conducted three times using stem cells derived from the fetal life support system
from the same donor, and similar trends in fold-increases of cord blood cells were demonstrated with co-culture.
Fig. 10. Capacity to maintain CD34þ cells by stem cells derived from the fetal life support system. Human stem cells derived from the fetal life support system (AM-Epi, AM-Mes,
and WJ-MSCs), positive control (HESS-5), and negative control (human ﬁbroblasts) were co-cultured with cord blood CD34þ cells for 5 days. Subsequently, cord blood cells were
collected and analyzed with ﬂow cytometry to determine the percentage of hematopoietic stem cell fraction (CD34þ CD45 cells). The red frame represents the CD34þ CD45
fraction.
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Fig. 11. Hematopoietic activity of CD34þ cells in the cord blood after co-culture. Hu-
man stem cells derived from the fetal life support system (AM-Epi, AM-Mes, and WJ-
MSCs), positive control (HESS-5), cell control (human ﬁbroblasts), and negative control
(NC) without feeder cells were co-cultured with cord blood CD34þ cells for 5 days.
Subsequently, cord blood cells were collected and analyzed with the CFU-GM assay.
*p < 0.05 (One-way ANOVA, Tukey's post-hoc test).
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support system
The three types of stem cells derived from the fetal life support
system (AM-Epi, AM-Mes, WJ-MSCs) that were isolated and
cultured from the same donor in the present study all exhibited a
cell surface marker proﬁle that met the minimal criteria for MSCs
[19]. This is consistent with previously reported results on AM-
Epi, AM-Mes, and WJ-MSCs [4,21,25]. Although AM-Epi origi-
nates from epithelial cells, they lost the expression of epithelial
markers and began expressing mesenchymal markers with sub-
culturing. A previous study showed that this phenomenon of a
morphological transition into mesenchymal cells is observed
when preparing AM-Epi samples, indicating that a similar modi-
ﬁcation is also occurring at the gene level [22]. This phenomenon
of epithelialemesenchymal transition is thought to be induced
through some type of stimulus during cell culture. However, there
is a possibility that a portion of mesenchymal cells contained in
the amnion epithelium fraction are selected through culturing
and consequently proliferate. Thus, the mechanistic elucidation of
this phenomenon is a future subject of investigation.
One of the characteristics of cell lines derived from the fetal life
support system that possess the ability to support hematopoiesis is
that they express MSCmarkers and exhibit differentiation potential
into bone and adipose tissue [12]. Moreover, it has also been shown
inmouse bonemarrow that cells that function in the hematopoietic
stem cell niche exhibit the morphology and function of MSCs [22].
In the future, it will be necessary to investigate the multipotency of
stem cells derived from the fetal life support system prepared in the
present study, and to elucidate the association between MSC
function and the capability of maintaining hematopoietic stem
cells.
4.3. Capacity to maintain hematopoietic stem cells in stem cells
derived from the fetal life support system
In the present study, we compared the ability to maintain
hematopoietic stem cells among different stem cells derivedfrom the fetal life support system. The results showed that the
proliferative capacity of cord blood CD34þ cells was high when
co-cultured with any of the three cell types (AM-Epi, AM-Mes, or
WJ-MSCs), and the levels were similar as the proliferative ca-
pacity of the HESS-5 positive control. In addition, the ability to
maintain hematopoietic stem cells was shown to be greater in
AM-Epi and in AM-Mes compared to WJ-MSCs based on ﬂow
cytometry and CFU-GM assay results. Robin et al. [12] generated
a cell line from human placenta without separating different cell
types and co-cultured these cells with CD34þ cells from human
cord blood, and subsequently found that CD34þ cells increased
2.2- to 7.7-fold. This proliferative capacity is near equivalent to
our results with isolated AM-Epi and AM-Mes (5.8-fold for AM-
Epi and 7.6-fold for AM-Mes). The numbers of CFU-GM colonies
of cord blood cells co-cultured with AM-Epi and with AM-Mes
were similar to when the cells were co-cultured with HESS-5,
which possess a high ability to maintain hematopoietic stem
cells, suggesting that the functional capabilities of AM-Epi and
AM-Mes to maintain hematopoietic stem cells are also high.
Although there are several previous studies that assessed the
capacity to maintain hematopoietic stem cells in co-culture ex-
periments of bone marrow MSCs or WJ-MSCs with hematopoi-
etic stem cells [26e30], none of them have made comparisons
among different types of stem cells derived from the fetal life
support system from the same donor in a co-culture system.
Thus, the observation that AM-Epi and AM-Mes have greater
capacities to maintain hematopoietic stem cells than WJ-MSCs is
a novel ﬁnding of this investigation.
Lu et al. [31] reported in vitro that umbilical cord-derived MSCs
and bone marrow MSCs have similar abilities to maintain he-
matopoietic stem cells. In the present investigation, the capacity to
maintain or support CFU-GMwas low in WJ-MSCs at a similar level
as ﬁbroblasts or the negative control without feeder cells. Although
the reason for this is not clear, it is postulated that the samples may
have contained cells that do not support hematopoietic stem cells
because WJ-MSCs were prepared using the explant method as
opposed to the collagenase enzymatic treatment. Recently, it was
reported in a co-transplantation experiment of human hemato-
poietic stem cells and human umbilical cord-derived MSCs into
NOD-SCID mice that the heterogeneity of MSCs is an important
factor that inﬂuences hematopoietic stem cell engraftment [32]. In
the future, a comparison of WJ-MSCs prepared with the enzymatic
method may be necessary. Additionally, although we co-cultured
each cell type with 1  105 cord blood CD34þ cells in the present
study, it may also be necessary to study the changes in proliferation
and maintenance capacity using different numbers of cells in the
co-culture protocol. In the future, to verify whether or not cells
obtained through co-culture maintain their hematopoietic activ-
ities in vivo, it will be necessary to transplant co-cultured cord
blood cells into immunodeﬁcient mice with ablated bone marrow
to examine the engraftment and to assess whether or not a rapid
improvement in hematopoietic recovery occurs.
Recently, clinical studies have been conducted in which umbil-
ical cord-derived MSCs were transplanted at the same time as he-
matopoietic stem cell transplantation, and these studies showed
that simultaneous MSC grafting can be performed safely and that
this simultaneous grafting promotes hematopoietic stem cell
engraftment, leading to early hematopoietic recovery [33e35]. It is
also desirable to investigatewhether or not hematopoietic stem cell
engraftment rates improve and whether or not hematopoietic re-
covery is promoted by AM-Epi, AM-Mes, and WJ-MSCs when they
are co-transplanted with human hematopoietic stem cells.
Recently, there have been few studies that investigated the
mechanism of action of hematopoietic stem cell engraftment
enhancement by MSCs derived from the fetal life support system.
E. Nishikawa et al. / Regenerative Therapy 4 (2016) 48e6160Lee et al. simultaneously transplanted human hematopoietic stem
cells and human umbilical cord-derived MSCs in NOD-SCID mice,
and found that the expression of MCP-1, RANTES, EGF, and VEGF
from MSCs is important in hematopoietic stem cell engraftment
[32]. Moreover, Chhabra et al. reported that the PDGF-B signaling
pathway plays a key role inmaintaining hematopoietic stem cells in
placental trophoblasts [36]. In the future, by comprehensively
investigating and elucidating the molecular mechanism regarding
hematopoietic stem cell maintenance by stem cells derived from
the fetal life support system, it is anticipated that it would be
possible to identify cells with greater grafting effects and to
establish optimal methods for cell preparation, collection, preser-
vation, and transplantation.
5. Conclusion
We tried to identify stem cells from organs of the fetal life
support system such as the placenta and umbilical cord, and
analyzed capacities to maintain hematopoietic stem cells. As a
result, AM-Epi and with AM-Mes possessed a high ability to
maintain hematopoietic stem cells, suggesting that the functional
capabilities of AM-Epi and AM-Mes to maintain hematopoietic
stem cells are also high. These ﬁndings indicated that cells derived
from the fetal life support system such as AM-Epi and AM-Mes can
be anticipated as potential cell sources for clinical application in cell
therapies for the purpose of enhancing graft survival during he-
matopoietic stem cell transplantation.
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